Asset Details
Do you wish to reserve the book?
Desmoglein-2 was a novel cancer-associated fibroblasts-related biomarker for oral squamous cell carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Desmoglein-2 was a novel cancer-associated fibroblasts-related biomarker for oral squamous cell carcinoma
Do you wish to request the book?
Desmoglein-2 was a novel cancer-associated fibroblasts-related biomarker for oral squamous cell carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Desmoglein-2 was a novel cancer-associated fibroblasts-related biomarker for oral squamous cell carcinoma
2025
Overview
Background
Oral squamous cell carcinoma (OSCC) is the most common type of oral cancer with alarmingly high morbidity. The cancer-associated fibroblasts (CAFs) play a pivotal role in tumor development, while their specific mechanisms in OSCC remains largely unclear. Our object is to explore a CAFs-related biomarker in OSCC.
Methods
Single-cell RNA sequencing (ScRNA-seq) analysis was used to pinpoint CAF clusters in OSCC samples. Differentially expressed genes and Cox regression analyses were used to identify candidate genes, and their functions were evaluated using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. The prognostic performance of the identified biomarker was evaluated using receiver operating characteristic analysis. The qPCR and western blot were used to assess gene expression. The hub gene related immune characteristics were analyzed in independent cohorts, and gene expression differences between different immunotherapy response groups were investigated using Pearson correlation analysis.
Results
Desmoglein-2 (
DSG2
) was identified as a CAFs-related biomarker in OSCC exhibiting elevated expression compared to controls and being associated with poor prognosis. Enrichment analyses revealed that
DSG2
was involved in signal transduction pathways like focal adhesion. The Area Under Curve values of
DSG2
in predicting prognosis exceeded 0.6 in both training-set and validation-set. Furthermore, patients with low
DSG2
expression were more likely to benefit from immunotherapy than those
DSG2
highly expressed patients.
Conclusion
Our study identified
DSG2
as a reliable CAFs-related prognostic biomarker in OSCC, providing a new reference for the mechanistic understanding and target therapy of this malignancy.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antigens
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Cancer
/ Cancer-associated fibroblasts
/ Cancer-Associated Fibroblasts - metabolism
/ Carcinoma, Squamous Cell - genetics
/ Carcinoma, Squamous Cell - metabolism
/ Carcinoma, Squamous Cell - pathology
/ Datasets
/ DSG2
/ Female
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Male
/ Medicine
/ Methods
/ Mouth Neoplasms - metabolism
/ Oral and Maxillofacial Surgery
/ Oral squamous cell carcinoma
/ Reagents
/ Tongue
